These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 33096281)
1. Effect of First-Line Ziconotide Intrathecal Drug Therapy for Neuropathic Pain on Disability, Emotional Well-Being, and Pain Catastrophizing. Shao MM; Khazen O; Hellman A; Czerwinski M; Dentinger R; DiMarzio M; Gillogly M; Hadanny A; Argoff C; Pilitsis JG World Neurosurg; 2021 Jan; 145():e340-e347. PubMed ID: 33096281 [TBL] [Abstract][Full Text] [Related]
2. Use of Low Dose Ziconotide as First-Line Intrathecal Monotherapy. Prusik J; Argoff C; Peng S; Pilitsis JG Neuromodulation; 2017 Jun; 20(4):386-391. PubMed ID: 27492135 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM). Deer T; Rauck RL; Kim P; Saulino MF; Wallace M; Grigsby EJ; Huang IZ; Mori F; Vanhove GF; McDowell GC Pain Pract; 2018 Feb; 18(2):230-238. PubMed ID: 28449352 [TBL] [Abstract][Full Text] [Related]
4. Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability. Pope JE; Deer TR Neuromodulation; 2015 Jul; 18(5):414-20. PubMed ID: 25708382 [TBL] [Abstract][Full Text] [Related]
5. Bolus intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study. Mohammed SI; Eldabe S; Simpson KH; Brookes M; Madzinga G; Gulve A; Baranidharan G; Radford H; Crowther T; Buchser E; Perruchoud C; Batterham AM Neuromodulation; 2013; 16(6):576-81; discussion 582. PubMed ID: 23205907 [TBL] [Abstract][Full Text] [Related]
6. Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options. Deer TR; Pope JE; Hanes MC; McDowell GC Pain Med; 2019 Apr; 20(4):784-798. PubMed ID: 30137539 [TBL] [Abstract][Full Text] [Related]
11. Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics. Sanford M CNS Drugs; 2013 Nov; 27(11):989-1002. PubMed ID: 23999971 [TBL] [Abstract][Full Text] [Related]
12. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain. Wermeling DP; Berger JR Pharmacotherapy; 2006 Mar; 26(3):395-402. PubMed ID: 16503720 [TBL] [Abstract][Full Text] [Related]
13. Acute rhabdomyolysis in a patient with long-term exposure to intrathecal ziconotide: a case report. Horazeck C; Huh AS; Huh BK Pain Pract; 2015 Mar; 15(3):E34-9. PubMed ID: 25565390 [TBL] [Abstract][Full Text] [Related]
14. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Webster LR; Fakata KL; Charapata S; Fisher R; MineHart M Pain Med; 2008 Apr; 9(3):282-90. PubMed ID: 18366508 [TBL] [Abstract][Full Text] [Related]
15. [Experience in treatment of patients with neuropathic facial pain using ziconotide]. Lux EA; Rasche D Schmerz; 2011 Aug; 25(4):434-9. PubMed ID: 21818721 [TBL] [Abstract][Full Text] [Related]
16. Ziconotide intrathecal delivery as treatment for secondary therapeutic failure of motor cortex stimulation after 6 years. Voirin J; Darie I; Fischer D; Simon A; Rohmer-Heitz I; Proust F Neurochirurgie; 2016 Oct; 62(5):284-288. PubMed ID: 27771111 [TBL] [Abstract][Full Text] [Related]
17. Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain. McDowell GC; Pope JE Neuromodulation; 2016 Jul; 19(5):522-32. PubMed ID: 26856969 [TBL] [Abstract][Full Text] [Related]
18. Successful reduction of neuropathic pain associated with spinal cord injury via of a combination of intrathecal hydromorphone and ziconotide: a case report. Saulino M Spinal Cord; 2007 Nov; 45(11):749-52. PubMed ID: 17310258 [TBL] [Abstract][Full Text] [Related]
19. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Wallace MS; Kosek PS; Staats P; Fisher R; Schultz DM; Leong M Pain Med; 2008 Apr; 9(3):271-81. PubMed ID: 18366507 [TBL] [Abstract][Full Text] [Related]
20. Ziconotide Combination Intrathecal Therapy for Noncancer Pain Is Limited Secondary to Delayed Adverse Effects: A Case Series With a 24-Month Follow-Up. Hayek SM; Hanes MC; Wang C; Veizi IE Neuromodulation; 2015 Jul; 18(5):397-403. PubMed ID: 25655991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]